JCSE01.09 Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in advNSCLC

MLA

Qing Zhou, et al. “JCSE01.09 Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in AdvNSCLC.” Journal of Thoracic Oncology, vol. 13, Oct. 2018, pp. S311–12. EBSCOhost, https://doi.org/10.1016/j.jtho.2018.08.217.

APA

Qing Zhou, M. Zheng, Xiao-Yan Bai, Y. Chakraborti, Yue-Li Sun, Zhen Wang, J.-J. Yang, X. Lv, Y-L. Wu, S. Zhao, Bin Gan, J. Callister, H. Chen, Chong-Rui Xu, Hai-Yan Tu, X. Zhang, Bin-Chao Wang, & A. Myers. (2018). JCSE01.09 Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in advNSCLC. Journal of Thoracic Oncology, 13, S311–S312. https://doi.org/10.1016/j.jtho.2018.08.217

Chicago

Qing Zhou, M. Zheng, Xiao-Yan Bai, Y. Chakraborti, Yue-Li Sun, Zhen Wang, J.-J. Yang, et al. 2018. “JCSE01.09 Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in AdvNSCLC.” Journal of Thoracic Oncology 13 (October): S311–12. doi:10.1016/j.jtho.2018.08.217.